Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7466939 | 0.84 | ALDH1A1 (0.56) | ALDH1A1MAPTCES1CES2TSHR | |
| SCHEMBL5216279 | 0.78 | LMNA (0.54) | SRD5A2LMNAALDH1A1MAPTL3MBTL1 | |
| SCHEMBL5215323 | 0.78 | ALDH1A1 (0.56) | POLBLMNAALDH1A1MAPT | |
| SCHEMBL7081998 | 0.77 | SMN1; SMN2 (0.67) | MAPK1POLBGAAALDH1A1MAPT | |
| SCHEMBL6771037 | 0.77 | ALDH1A1 (0.62) | MAPK1LMNAGAAALDH1A1MAPT | |
| SCHEMBL5223686 | 0.77 | SMN1; SMN2 (0.62) | SRD5A2MAPK1POLBALDH1A1MAPT | |
| SCHEMBL6331530 | 0.77 | SMN1; SMN2 (0.46) | LMNAALDH1A1MAPTL3MBTL1HDAC3 | |
| SCHEMBL9013254 | 0.77 | MEN1 (0.50) | LMNAALDH1A1MAPT | |
| SCHEMBL15648678 | 0.76 | L3MBTL1 (0.54) | SRD5A2MAPK1POLBLMNAGAA | |
| SCHEMBL526662 | 0.75 | SMN1; SMN2 (0.58) | POLBALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | BRISTOL-MYERS SQUIBB CO. | 2005-06-09 | — | — | US | disclosed |
| EP-1154996-B1 | AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | ORTHO MCNEIL PHARM INC (US) | 2003-11-05 | — | — | EP | disclosed |
| US-6369228-B2 | ANTICONVULSANTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-04-09 | — | — | US | disclosed |
| US-20010044452-A1 | Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain | CARSON JOHN R (US) | 2001-11-22 | — | — | US | disclosed |
| EP-1154996-A2 | AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | Ortho-McNeil Pharmaceutical, Inc. (US) | 2001-11-21 | — | — | EP | disclosed |
| US-6191142-B1 | Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2001-02-20 | — | — | US | disclosed |
| WO-2000048584-A2 | AROYL AMINOACYL PYRROLES FOR USE IN THE TREATMENT OF NEUROPATHIC PAIN | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2000-08-24 | — | — | WO | disclosed |
| US-5565456-A | Anxiolytic aroyl piperidinyl and piperazinylacyl pyrroles | ORTHO PHARMACEUCTICAL CORPORATION (US) | 1996-10-15 | — | — | US | disclosed |
| US-5418236-A | Anxiolytic aroyl piperidinyl and piperazinylacyl pyrroles | ORTHO PHARMACEUTICAL CORPORATION (US) | 1995-05-23 | — | — | US | disclosed |
| US-5332736-A | Anti-convulsant aroyl aminoacylpyrroles | ORTHO PHARMACEUTICAL CORPORATION (US) | 1994-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010044452-A1 | Aroyl aminoacyl pyrroles for use in the treatment of neuropathic pain | OPRL1, AADAT, OPRK1 | SRD5A2 3574/4885MAPK1 4284/4885POLB 3214/4885 |
| US-20050124664-A1 | Urea thiadiazole inhibitors of plasminogen activator inhibior-1 | SERPINE1, SERPINC1, SERPINB1 | SRD5A2 182/4885MAPK1 907/4885POLB 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.